381 related articles for article (PubMed ID: 30193532)
1. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
2. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
Walsh GM
Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.
Walsh GM
Adv Pharmacol; 2023; 98():31-54. PubMed ID: 37524491
[TBL] [Abstract][Full Text] [Related]
5. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
6. Biologics for asthma and allergy.
Walsh GM
Curr Opin Otolaryngol Head Neck Surg; 2017 Jun; 25(3):231-234. PubMed ID: 28234780
[TBL] [Abstract][Full Text] [Related]
7. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
8. An update on emerging drugs for asthma.
Walsh GM
Expert Opin Emerg Drugs; 2012 Mar; 17(1):37-42. PubMed ID: 22292562
[TBL] [Abstract][Full Text] [Related]
9. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
10. Asthma Yardstick Update: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
Oppenheimer JJ; Borish L
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):660-661. PubMed ID: 30172715
[No Abstract] [Full Text] [Related]
11. Anti-IL-4/-13 based therapy in asthma.
Walsh GM
Expert Opin Emerg Drugs; 2015 Sep; 20(3):349-52. PubMed ID: 26021492
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
14. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
15. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
16. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
17. Selecting the right biologic for your patients with severe asthma.
Manka LA; Wechsler ME
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):406-413. PubMed ID: 30056149
[TBL] [Abstract][Full Text] [Related]
18. The use of biologic therapies for the management of pediatric asthma.
Lovinsky-Desir S
Pediatr Pulmonol; 2020 Mar; 55(3):803-808. PubMed ID: 31880870
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
De Boever EH; Ashman C; Cahn AP; Locantore NW; Overend P; Pouliquen IJ; Serone AP; Wright TJ; Jenkins MM; Panesar IS; Thiagarajah SS; Wenzel SE
J Allergy Clin Immunol; 2014 Apr; 133(4):989-96. PubMed ID: 24582316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]